Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead's HIV Quad Pill Passes Tolerability Test, But Not With A Straight "A"

Executive Summary

By and large, Gilead's latest Phase II results for its fixed-dose, four-drug "Quad" regimen for HIV and stand-alone data on its novel GS-9350 booster satisfied clinicians and analysts when it came to the commercially crucial tolerability test

You may also be interested in...



Gilead Clarifies Quad Will Come First, Over Detailing For Triple Combo Complera

Company is pursuing priority review, eyes FDA approval in mid-2012. If Quad is cleared, newly approved Complera will take back seat.

Gilead Clarifies Quad Will Come First, Over Detailing For Triple Combo Complera

Company is pursuing priority review, eyes FDA-approval in mid-2012. If Quad is cleared, newly-approved Complera will take back seat.

Gilead's Quad Poised To Take Chunk Of Atripla's Market, If Phase III Results Hold Up

Solid efficacy with fewer psych effects than Atripla continue in full-length version of Phase II trials. However, hopes for superior performance have started to wane.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051973

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel